Sonidegib

Sonidegib
Clinical data
Trade names	Odomzo
Other names	LDE225, erismodegib
AHFS/Drugs.com	Monograph
MedlinePlus	a615034
License data	EU EMA: by INN; US DailyMed: Sonidegib;
Pregnancy; category	Contraindicated (X);
Routes of; administration	By mouth
Drug class	Antineoplastic agents
ATC code	L01XJ02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	<10%
Protein binding	>97%
Metabolism	Liver (CYP3A)
Elimination half-life	~28 days
Excretion	Feces (~70%), urine (30%)
Identifiers
	IUPAC name N-[6-[(2S,6R)-2,6-Dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide;
CAS Number	956697-53-3 ;
PubChem CID	24775005;
DrugBank	DB09143;
ChemSpider	25027390;
UNII	0RLU3VTK5M;
KEGG	D10119; as salt: D10729;
ChEBI	CHEBI:90863 ;
ChEMBL	ChEMBL2105737;
CompTox Dashboard (EPA)	DTXSID501009335 ;
Chemical and physical data
Formula	C26H26F3N3O3
Molar mass	485.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F;
	InChI InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+; Key:VZZJRYRQSPEMTK-CALCHBBNSA-N;

Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.^[1]

Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism).^[4]^[5]

^ ^a ^b ^c ^d Cite error: The named reference Odomzo FDA label was invoked but never defined (see the help page).
^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Summary Basis of Decision (SBD) for Odomzo". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "LDE225 - PubChem". PubChem. National Institutes of Health. Retrieved 16 February 2014.
^ Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, et al. (June 2010). "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist". ACS Medicinal Chemistry Letters. 1 (3): 130–4. doi:10.1021/ml1000307. PMC 4007689. PMID 24900187.